FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549

OMB Number: STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Sullivan Timothy Eugene						2. Issuer Name and Ticker or Trading Symbol Apellis Pharmaceuticals, Inc. [APLS]									Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) C/O APELLIS PHARMACEUTICALS, INC.						ate o 05/2		iest Tra	ansactic	on (Mor	nth/Day/Year)	X Officer (give title Other (specify below) below) Chief Financial Officer						fy			
100 FIFTH AVENUE, 3RD FLOOR					4. If	Ame	ndme	nt, Dat	e of Ori	ginal F	iled (Month/D	r)	6. Individual or Joint/Group Filing (Check Applicable Line)								
(Street) WALTH	IAM MA 02451												X Form filed by One Reporting Person Form filed by More than One Reporting Person								
(City)	(State) (Zip)				Ru	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
			le I -	Non-Deri						'				ciall					7 11-1		
1. Title of Security (Instr. 3)			2. Transactio Date (Month/Day/Y	ear) E:	2A. Deemed Execution Date, if any (Month/Day/Year)		ate,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially Owned Following Reported		ly	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount	(A) or (D)	Price		Transactio				(ear 1)				
Common Stock													56,232		32	I(1)		The Timothy E Sullivan Irrevocable Trust of 2023			
Common Stock 06/			06/05/202	23	3			M ⁽²⁾	П	69,779	Α	\$10.0	3	147,4	192	D			\neg		
Common Stock 06/05			06/05/202	23				S ⁽²⁾		1,600	D	\$90.604	14 ⁽³⁾	145,892		D					
Common	mmon Stock 06/05/2023				23				S ⁽²⁾		30,609	D	\$87.788	36 ⁽⁴⁾	115,283		D				
Common	Stock			06/05/202	23				S ⁽²⁾		7,064	D	\$88.364	19 ⁽⁵⁾	108,219		D				
Common	Stock			06/05/202	23				S ⁽²⁾		30,506	D	\$89.825	59 ⁽⁶⁾	77,7	13	D				
		Т	able	ll - Deriva - اا : e.g., ا							sposed of				Owned						
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	Exec if any	Deemed cution Date,	4. Transac	I. Transaction Code (Instr.		umber ivative urities uired or oosed O) tr. 3, 4 5)	f 6. Date Ex Expiration (Month/Da		rcisable and Date	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Numb derivati Securiti Benefic Owned Followin Reporte Transac (Instr. 4)	ve ies ially ng ed ction(s)	10. Owners Form: Direct (I or Indire (I) (Instr	hip of Be D) Ov ect (In	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exer	cisable	Expiration Date	Title	Amor or Numl of Share	oer							
Stock Option (Right to Buy)	\$10.03	06/05/2023			M ⁽²⁾			69,779	9	(7)	10/18/2027	Comn		79	\$0	288,	840	D			

- 1. The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
- 2. This is a scheduled exercise & sale from 10b5-1 trading plan.
- 3. This transaction was executed in multiple trades at prices ranging from \$90.380 \$90.790. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 4. This transaction was executed in multiple trades at prices ranging from \$87.155 \$88.150. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 5. This transaction was executed in multiple trades at prices ranging from \$88.160 \$89.130. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 6. This transaction was executed in multiple trades at prices ranging from \$89.375 \$90.370. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 7. This option was granted on October 18, 2017 and fully vested.

/s/s David Watson, attorney-infact for Timothy Sullivan

06/06/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.